Stockscreener 앱 받기
4.23
1.86%
-0.08
시간 외 거래:
4.23
전일 마감가:
$4.31
열려 있는:
$4.24
하루 거래량:
25,377
Relative Volume:
0.17
시가총액:
$37.31M
수익:
$1.07M
순이익/손실:
$-18.24M
주가수익비율:
-1.9901
EPS:
-2.1255
순현금흐름:
$-17.26M
1주 성능:
-4.08%
1개월 성능:
-8.04%
6개월 성능:
+94.93%
1년 성능:
+78.48%
1일 변동 폭
$4.2104
$4.25
1주일 범위
$4.03
$4.42
52주 변동 폭
$1.81
$4.8918
Lisata Therapeutics Inc Stock (LSTA) Company Profile
명칭
Lisata Therapeutics Inc
전화
908-229-2590
주소
110 ALLEN ROAD, BASKING RIDGE
Compare LSTA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
4.23 | 38.02M | 1.07M | -18.24M | -17.26M | -2.1255 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lisata Therapeutics Inc 주식(LSTA)의 최신 뉴스
Lisata Extends Kuva Labs Acquisition Term Sheet Timeline - TipRanks
Lisata Extends Kuva Tender Offer Term Sheet to March 7 as Acquisition Talks Continue - TradingView
Will Lisata Therapeutics Inc. stock go up in YEARJuly 2025 Analyst Calls & Technical Pattern Based Buy Signals - mfd.ru
LSTA SEC FilingsLisata Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Lisata Therapeutics (LSTA) Price Target Increased by 19.30% to 11.56 - Nasdaq
LSTA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Why is Lisata Therapeutics Inc. stock going downAnalyst Downgrade & Precise Entry and Exit Recommendations - mfd.ru
What is the long term forecast for Lisata Therapeutics Inc. stockJuly 2025 Decliners & Comprehensive Market Scan Insights - mfd.ru
Can Lisata Therapeutics Inc. keep up with sector leadersTrade Risk Summary & Free Accurate Trade Setup Notifications - mfd.ru
LSTA PE Ratio & Valuation, Is LSTA Overvalued - Intellectia AI
Will Lisata Therapeutics Inc. (8NE) stock benefit from sector leadershipMarket Risk Summary & Accurate Intraday Trade Tips - mfd.ru
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareho - GuruFocus
Halper Sadeh LLC Reminds Shareholders of SKYT, NATH, SNCY, LSTA of the Firm’s Investigations - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Swing Trade: Can SILA withstand a market correctionTrade Volume Report & Technical Pattern Alert System - baoquankhu1.vn
Signal Recap: Will Lisata Therapeutics Inc stock benefit from M ARisk Management & Technical Confirmation Trade Alerts - baoquankhu1.vn
What Does the Market Think About Lisata Therapeutics Inc? - Benzinga
Halper Sadeh LLC Investigates Potential Violations by Multiple Companies - intellectia.ai
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights - Finviz
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA - Finansavisen
Lisata regains full rights to certepetide in Greater China region By Investing.com - Investing.com Canada
Deal Watch: Kuva Labs To Go Public Via Merger With Licensing Partner Lisata - Citeline News & Insights
Lisata Therapeutics and Qilu Pharmaceutical end certepetide license agreement By Investing.com - Investing.com South Africa
Lisata Therapeutics and Qilu Pharmaceutical end certepetide license agreement - Investing.com Nigeria
Lisata regains full rights to certepetide in Greater China region - Investing.com
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide - marketscreener.com
Lisata Therapeutics (LSTA) Ends Licensing Agreement with Qilu Ph - GuruFocus
Lisata Therapeutics ends Qilu certepetide collaboration deal - TipRanks
Lisata regains China rights to pancreatic cancer drug - Proactive financial news
Lisata Therapeutics and Qilu Pharmaceutical Terminate License Agreement - TradingView
Cancer drug rights shift: Lisata takes back certepetide in China - stocktitan.net
Lisata shares nearly double on buyout offer: Here are the details - MSN
Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals - RTTNews
Lisata Therapeutics to be acquired by Kuva Labs in $4.00-per-share cash deal - MSN
Lisata Therapeutics surges on Kuva Labs takeover proposal carrying hefty premium - MSN
Lisata Therapeutics And 2 Other Penny Stocks Worth Watching - Yahoo Finance
Kuva Labs to acquire Lisata Therapeutics for $4 per share By Investing.com - Investing.com Nigeria
How The Evolving Story For Lisata Therapeutics (LSTA) Is Reshaping Its Valuation Outlook - Yahoo Finance
Lisata Therapeutics (LSTA) Downgraded by Brookline Capital | LST - GuruFocus
Halper Sadeh Investigates Fairness of Lisata's $4.00 Sale to Kuva Labs - Intellectia AI
LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders - The AI Journal
Lisata Shares Nearly Double On Buyout Offer: Here Are The Details - Asianet Newsable
Lisata Therapeutics to be Acquired by Kuva Labs for $4.00 Per Share - citybiz
Kuva Labs, Inc. entered into a binding term sheet to acquire Lisata Therapeutics, Inc. for $36.7 million. - marketscreener.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (NasdaqSNCY), Ventyx Biosciences, Inc. (Nasdaq - GlobeNewswire Inc.
Dow Surges 300 Points; Netflix Shares Fall After Q4 Results - Benzinga
Market movers: Kraft Heinz, Lisata Therapeutics, Halliburton, Johnson & Johnson... - Proactive financial news
Lisata stock soars after Kuva Labs acquisition offer at 85% premium By Investing.com - Investing.com South Africa
Lisata stock soars after Kuva Labs acquisition offer at 85% premium - Investing.com Nigeria
Lisata Therapeutics Inc (LSTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.69%
0.68%
자본화:
|
볼륨(24시간):